According to the Alzheimer’s Association, more than 6 million Americans and their families are living with Alzheimer’s disease. To determine if a person has the disease and rule out other possible causes of cognitive disfunction, doctors use several methods and tools, such as memory and problem-solving tests, biomarker tests and brain scans. Companies and scientists are engaged in harnessing the power of artificial intelligence (AI) to improve diagnosis. Here are three examples.

RetiSpec, a Toronto-based medical imaging company, claims to have developed an AI algorithm for its eye scanner that can detect signs of Alzheimer’s 20 years before symptoms develop, as well as Parkinson’s, vascular dementia and amyotrophic lateral sclerosis (ALS). 

California-based NeuroVision Imaging uses its AI-enhanced retinal imaging system to look for the buildup of certain proteins or blood vessels with a twisted shape, which are both associated with Alzheimer’s disease.

Rui Chang, Ph.D., a researcher at the University of Arizona College of Medicine, built an AI model to identify genetic triggers linked to Alzheimer’s, which would otherwise potentially take a decade to identify. His model will be tested in a clinical trial led by PATH Biotech, an AI-powered medical solutions company founded by Chang.